Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Authors: Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick, Marc Sanson, Alba A. Brandes, Paul M. Clément, S. C. Erridge, Michael A. Vogelbaum, Anna K. Nowak, Jean Français Baurain, Warren Mason, Helen Wheeler, Olivier Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap C. Reijneveld, Roelien H. Enting, Francesca Caparrotti, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, F. Dhermain, Iris de Heer, Kenneth Aldape, Robert B. Jenkins, Hendrikus J. Dubbink, Johan M. Kros, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Pim J. French, Brigitta G. Baumert - The Lancet 2021 cited by 327